| Expression pattern: |
UP |
| Associated gene: |
ABL2, SMAD2/3, YAP, PGD-219aa |
| Associated microRNA: |
miR-16-5p |
| Biological function: |
promotes proliferation and migration/metastasis; inhibits apoptosis; promotes EMT |
| Molecular mechanism: |
ceRNA sponging miR-16-5p to de-repress ABL2; modulates SMAD2/3 and YAP signaling; encodes PGD-219aa protein |
| Biological pathway or process: |
SMAD2/3 (promotes); Hippo/YAP (promotes); proliferation (promotes); migration (promotes); metastasis (promotes); apoptosis (inhibits); EMT (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; Western Blot; IF (Immunofluorescence); IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
circPGD expression increased within GC samples and was related to lymph node metastasis (LNM) and tumor size; potential diagnostic marker for GC |
| Description: |
circPGD (hsa_circ_0009735), derived from PGD, is up-regulated in gastric cancer tissues and cell lines and correlates with larger tumor size and lymph node metastasis. It promotes proliferation, migration/metastasis and EMT while inhibiting apoptosis by sponging miR-16-5p to de-repress ABL2 and activating SMAD2/3 and Hippo/YAP-related signaling. circPGD also encodes a tumor-promoting protein (PGD-219aa) that similarly enhances malignant phenotypes. |
| Confidence score: |
0.8072 |